Sunovion’s Kynmobi Gets FDA Approval for Parkinson’s Disease ‘Off Episodes’

Sunovion’s sublingual film-therapy Kynmobi (apomorphine hydrochloride) has received the FDA’s approval for treating “off episodes” caused by Parkinson’s disease.

The drug has been approved for treating the disruptive episodes in which symptoms reemerge or worsen after a patient’s medication wears off or fails to take effect. The symptoms include tremors, stiffness and slowed movement.

Up to 60 percent of Parkinson’s disease patients experience off episodes within four to six years of diagnosis.